Nonsurgical Salvage Local Therapies for Radiorecurrent Prostate Cancer: A Systematic Review and Meta-analysis.


Journal

European urology oncology
ISSN: 2588-9311
Titre abrégé: Eur Urol Oncol
Pays: Netherlands
ID NLM: 101724904

Informations de publication

Date de publication:
04 2020
Historique:
received: 28 10 2018
revised: 06 12 2018
accepted: 20 12 2018
pubmed: 15 8 2019
medline: 15 12 2020
entrez: 15 8 2019
Statut: ppublish

Résumé

Different nonsurgical therapeutic strategies can be adopted for intraprostatic relapse of prostate cancer after primary radiotherapy, including re-irradiation (with brachytherapy [BT] or external beam radiotherapy [EBRT]), high-intensity focused ultrasound (HIFU), and cryotherapy. The main issues to consider when choosing nonsurgical salvage local therapies are local tumor control and significant genitourinary toxicity. To conduct a systematic review and meta-analysis of the role of nonsurgical salvage modalities in patients with radiorecurrent prostate cancer and associated clinical outcomes and toxicity profiles. We performed a critical review of the Medline, Scopus, and ClinicalKey databases from January 1, 2000 through February 1, 2018 according to the Preferred Reporting Items and Meta-Analyses statement. To assess the overall quality of the literature reviewed, we used a modified Delphi tool for case-series studies. A total of 64 case-series studies were included, corresponding to a cohort of 5585 patients. The modified Delphi checklist evidenced high methodological quality overall (mean quality score of 80.6%). Biochemical control rates were lowest for patients treated with HIFU (58%, 95% confidence interval [CI] 47-68%) and highest for patients treated with BT (69%, 95% CI 62-76%) and EBRT (69%, 95% CI 53-83%). The lowest prevalence of incontinence was for patients treated with BT (3%, 95% CI 0-6%; I Nonsurgical therapeutic options, especially BT, showed good outcomes in terms of biochemical control and tolerability in the local recurrence setting. The current analysis demonstrated that nonsurgical salvage local therapies offer a chance of a curative local approach in radiorecurrent prostate cancer. However, high-quality data from prospective trials are needed to validate long-term outcomes from nonsurgical strategies for the treatment of intraprostatic recurrence after previous radiotherapy.

Identifiants

pubmed: 31411996
pii: S2588-9311(18)30219-0
doi: 10.1016/j.euo.2018.12.011
pii:
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

183-197

Informations de copyright

Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Gianluca Ingrosso (G)

Department of Radiation Oncology, Tor Vergata General Hospital, University of Rome "Tor Vergata", Rome, Italy.

Carlotta Becherini (C)

Department of Radiation Oncology, A.O.U. Careggi, University of Florence, Florence, Italy.

Andrea Lancia (A)

Radiation Oncology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy. Electronic address: andrea.lancia.dr@gmail.com.

Saverio Caini (S)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Networking, Florence, Italy.

Piet Ost (P)

Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.

Giulio Francolini (G)

Department of Radiation Oncology, A.O.U. Careggi, University of Florence, Florence, Italy.

Morten Høyer (M)

Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.

Marta Bottero (M)

Department of Radiation Oncology, Tor Vergata General Hospital, University of Rome "Tor Vergata", Rome, Italy.

Alberto Bossi (A)

Department of Radiotherapy, Gustave-Roussy Institute, Villejuif, France.

Thomas Zilli (T)

Radiation Oncology, Geneva University Hospital, Geneva, Switzerland.

Daniele Scartoni (D)

Proton Treatment Center, Azienda Provinciale per i Servizi Sanitari, Trento, Italy.

Lorenzo Livi (L)

Department of Radiation Oncology, A.O.U. Careggi, University of Florence, Florence, Italy.

Riccardo Santoni (R)

Department of Radiation Oncology, Tor Vergata General Hospital, University of Rome "Tor Vergata", Rome, Italy.

Irene Giacomelli (I)

Proton Treatment Center, Azienda Provinciale per i Servizi Sanitari, Trento, Italy.

Beatrice Detti (B)

Department of Radiation Oncology, A.O.U. Careggi, University of Florence, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH